Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE These data underscore the importance of CDK4/6 signaling in HR+/HER2‒ breast cancer and suggest that the interplay between steroid hormone and peptide growth factor signaling could drive dependence on CDK4/6 signaling.(Pfizer; NCT01740427). 31527167 2020
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 GeneticVariation disease BEFREE Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. 31151842 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE In this article, we review the published literature with regard to the rationale for CDK4/6-directed therapies in HER2+ BC and discuss ongoing clinical research and new challenges in the field. 31832106 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. 31444334 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by Federal Drug Administration and the European Medicines Agency for the treatment of advanced and metastatic HR+/HER2- breast cancer. 31777590 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Preclinical studies have demonstrated that CDK4/6 inhibitors can resensitize resistant HER2-positive breast cancer to anti-HER2 therapies. 31235441 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer. 30677445 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Three CDK4/6 inhibitors, palbociclib (PAL), ribociclib (RIB), and abemaciclib, when combined with letrozole (LET), have been approved as first-line therapy for postmenopausal women with metastatic HR+, HER2- breast cancer. 30847728 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE <b>Methods:</b> We reviewed clinical trials investigating the efficacy of CDK4/6 inhibitors for advanced or metastatic HR+/HER2- breast cancer. 31695840 2019
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Here, we performed a meta-analysis of randomized clinical trials (RCTs) to better define the benefit and the risk of CDK4/6 inhibitors plus ET for endocrine-sensitive or endocrine-resistant population in metastatic HR+/HER2- breast cancer. 30054831 2018
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE This review focuses on the recent reports of the essential role of PI3K/Akt/mTOR and CDK4/6/RB pathways in ER+ HER2- breast cancer. 29086897 2018
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE CDK4/6 inhibitors in HER2-positive breast cancer. 28325261 2017
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. 27564114 2016
Entrez Id: 1019
Gene Symbol: CDK4
CDK4
0.100 Biomarker disease BEFREE Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model. 23776583 2013